“Shift Toward Immunotherapy and Targeted Therapies”
One notable trend in the global oncology blockbuster drugs market is the shifting away from traditional chemotherapy toward more innovative treatments, particularly immunotherapies and targeted therapies. Immunotherapies, such as PD-1/PD-L1 inhibitors, have gained significant attention for their ability to harness the body’s immune system to target and destroy cancer cells. These therapies offer a more personalized approach to treatment, often tailored to the individual’s genetic profile or the specific characteristics of the cancer. Targeted therapies, on the other hand, focus on specific molecular targets or pathways that are crucial for cancer cell growth, providing a more precise and effective treatment with fewer side effects than conventional chemotherapy. As a result, these therapies are being adopted more widely in oncology practice, especially for cancers like melanoma, lung cancer, and lymphoma. The focus on reducing toxicity while improving outcomes has made immunotherapy and targeted therapies increasingly prominent in cancer care.
